Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.

Outside of the core registrational programs for these two important indications, we have several additional ongoing phase ...

Eli Lilly (NYSE: LLY) delivered a commanding third quarter, posting earnings and revenue that significantly exceeded ...

Eli Lilly (NYSE:LLY) shares rose 6% in the premarket on Thursday after the drugmaker beat Wall Street expectations with its ...

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

Pharmaceutical giant Eli Lilly posted stronger-than-expected third-quarter earnings and revenue on Thursday, fuelled by ...

Reports Q3 revenue $17.6B, consensus $16.07B. “Lilly delivered another strong quarter, with 54% revenue growth year-over-year driven by continued ...

Eli Lilly beat Q3 estimates with $7.02 EPS and $17.60 billion revenue, raising full-year guidance as Zepbound and Mounjaro ...

The drugmaker posted revenue of $17.6 billion in the period, which also topped Street forecasts. Six analysts surveyed by Zacks expected $16.01 billion. Lilly expects full-year earnings in the range ...

Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly ...

Recursion, Roche and Genentech unveiled the latest product of their nearly four-year artificial intelligence drug discovery collaboration. GSK ’s Blenrep was approved by the FDA for treatment of ...

Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.